Stocks and Investing Stocks and Investing
Mon, April 6, 2020

Kevin Caliendo Upgraded (TEVA) to Strong Buy on, Apr 6th, 2020


Published on 2024-10-27 02:10:14 - WOPRAI, Kevin Caliendo
  Print publication without navigation


Kevin Caliendo of UBS, Upgraded "Teva Pharmaceutical Industries Limited" (TEVA) to Strong Buy on, Apr 6th, 2020.

Kevin has made no other calls on TEVA in the last 4 months.



There are 6 other peers that have a rating on TEVA. Out of the 6 peers that are also analyzing TEVA, 3 agree with Kevin's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jacob Hughes of "Wells Fargo" Maintained at Hold with Increased Target to $12 on, Thursday, March 5th, 2020
  • Louise Chen of "Cantor Fitzgerald" Maintained at Hold with Increased Target to $15 on, Wednesday, February 12th, 2020
  • Sel Hardy of "CFRA" Maintained at Hold with Increased Target to $13 on, Wednesday, February 12th, 2020


These are the ratings of the 3 analyists that currently disagree with Kevin


  • David Risinger of "Morgan Stanley" Maintained at Sell with Decreased Target to $8 on, Thursday, April 2nd, 2020
  • Jason Gerberry of "B of A Securities" Maintained at Sell with Decreased Target to $7 on, Monday, March 23rd, 2020
  • Leland Gershell of "Oppenheimer" Maintained at Buy with Increased Target to $16 on, Thursday, February 13th, 2020
Contributing Sources